Impact of DAA Uptake in Controlling HCV Epidemic and Modeling Interventions for HCV Elimination Among HIV-infected Persons in San Diego
This is a retrospective and prospective study among people living with HIV (PLWH) that assesses hepatitis C (HCV) treatment uptake during periods before and after direct-acting antivirals (DAA) introduction, and its impact on the HCV epidemic among PLWH.
This study is a phase IV, open-label, single arm, multicentre study whose aim is to assess whether interferon-free and ribavirin-free Direct Acting Antiviral (DAA) Hepatitis C Virus (HCV) therapy with grazoprevir/elbasvir, will be feasible for the treatment of People who inject drugs (PWID) with recent injecting drug use and chronic HCV genotype 1 or 4 infection.
This study will recruit patients who have been diagnosed with acute (within 26 weeks) infection that are also infected with HIV (HIV/HCV coinfection). The goal of this trial is to find out if the treatment duration can be reduced from 12 weeks to 8 weeks in people who are infected with HCV genotype 1 and 4. A total of 80 patients will be enrolled. The drugs being used in this study are Zepatier (grazoprevir plus elbasvir) combined into one pill taken once-a-day.
The trial will enroll people infected with HCV and people coinfected with HIV/HCV to test the effectiveness of Harvoni treatment to improve central nervous system functioning. The study will use MRI and blood tests to measure the changes the brain.
Impact of Hepatitis C Virus Therapy on Central Nervous System Outcomes
To view the entire clinical trial information, click here